Tag: Antibody drug conjugate

The estimated cost for treatment with enfortumab vedotin (Padcev) is approximately $17,718 per 28-day cycle [1.2.2]. This article explores the question, 'How much does enfortumab vedotin cost in the US?', by examining pricing, influencing factors, and financial support systems.

Over the past two decades, the development of sophisticated targeted therapies like antibody-drug conjugates (ADCs) has revolutionized cancer treatment, highlighting the importance of understanding **what is a conjugate in medical terms**. A conjugate is a compound formed by chemically joining two or more different substances, with this strategic chemical union playing diverse and crucial roles in pharmacology and medicine.

Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most prostate cancer cells, with levels increasing in more advanced and aggressive disease. A **PSMA antibody drug** is a specialized therapy that leverages this protein to selectively target and destroy cancer cells while minimizing harm to healthy tissue. This article explains how this precision medicine works, who can benefit, and its potential side effects.

First approved by the U.S. Food and Drug Administration (FDA) in 2019 as a component of the drug Enhertu, deruxtecan serves as the highly potent cytotoxic payload within several advanced antibody-drug conjugates (ADCs). These conjugates, which specifically target cancer cells, represent a major advancement in targeted chemotherapy by delivering a powerful cell-killing agent directly to the tumor. The question, 'what does deruxtecan do?', is fundamentally about understanding this sophisticated delivery and attack system.

Over two decades, antibody-drug conjugates (ADCs) have transformed targeted cancer therapy, and the next-generation platform using a **DXd drug** as a payload is at the forefront of this innovation. This technology, pioneered by Daiichi Sankyo, is built around a potent topoisomerase I inhibitor, designed to precisely deliver chemotherapy to cancer cells while minimizing systemic harm.

In recent clinical trials, the targeted drug trastuzumab deruxtecan (Enhertu) demonstrated a 72% improvement in progression-free survival for certain patients with HER2-positive metastatic breast cancer compared to a different therapy. This innovative medication, which incorporates the chemotherapy payload **Deruxtecan**, represents a significant advancement in oncology by selectively delivering potent treatment directly to cancer cells.

According to the FDA, Tivdak was granted accelerated approval in 2021 for the treatment of recurrent or metastatic cervical cancer in adults who have progressed during or after previous chemotherapy. This targeted therapy, known by its generic name tisotumab vedotin-tftv, is a specialized antibody-drug conjugate (ADC) that functions differently from traditional chemotherapy by directly targeting cancer cells.

Over 50 different drugs begin with the prefix 'gem' or include it in their name, making clarification essential when asking 'What is the drug gem?'. In pharmacology, this prefix can refer to several distinct medications with entirely different uses and mechanisms of action, from cancer therapy to treating overactive bladder.